WTAP‐induced N 6 ‐methyladenosine of PD‐L1 blocked T‐cell‐mediated antitumor activity under hypoxia in colorectal cancer
Cancer Science · 2024
DOI: 10.1111/cas.16136 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, 2024. Verfasst von Qi-Zhi Liu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Surgery, Shanghai Fourth People's Hospital, School of Medicine, Tongji University, Shanghai, China. Hauptthemen laut MEDLINE: Adenosine, Colorectal Neoplasms, B7-H1 Antigen. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: "Special fund for scientific research startup" by Shanghai Fourth People's Hospital, The Science and Technology Commission of Shanghai Hongkou District, medical engineering of Shanghai Jiao Tong University.
Abstract (Originalsprache)
N 6 ‐Methyladenosine (m 6 A) is a important process regulating gene expression post‐transcriptionally. Programmed death ligand 1 (PD‐L1) is a major immune inhibitive checkpoint that facilitates immune evasion and is expressed in tumor cells. In this research we discovered that Wilms' tumor 1‐associated protein (WTAP) degradation caused by ubiquitin‐mediated cleavage in cancer cells (colorectal cancer, CRC) under hypoxia was inhibited by Pumilio homolog 1 (PUM1) directly bound to WTAP. WTAP enhanced PD‐L1 expression in a way that was m 6 A‐dependent. m 6 A “reader,” Insulin‐like growth factor 2 mRNA‐binding protein 2 (IGF2BP2) identified methylated PD‐L1 transcripts and subsequently fixed its mRNA. Additionally, we found that T‐cell proliferation and its cancer cell‐killing effects were prevented by overexpression of WTAP in vitro and in vivo. Overexpression prevented T cells from proliferating and killing CRC by maintaining the expression of PD‐L1. Further evidence supporting the WTAP–PD‐L1 regulatory axis was found in human CRC and organoid tissues. Tumors with high WTAP levels appeared more responsive to anti‐PD1 immunotherapy, when analyzing samples from patients undergoing treatment. Overall, our findings demonstrated a novel PD‐L1 regulatory mechanism by WTAP‐induced mRNA epigenetic regulation and the possible application of targeting WTAP as immunotherapy for tumor hypoxia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastrointestinal Surgery, Shanghai Fourth People's Hospital, School of Medicine, Tongji University, Shanghai, China.
- Department of Oncology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
ORCID-Profile: Xiao-Huang Tu
Förderung
- "Special fund for scientific research startup" by Shanghai Fourth People's Hospital
- The Science and Technology Commission of Shanghai Hongkou District
- medical engineering of Shanghai Jiao Tong University
Zitieren
APA
Liu, Q. Z., Zhang, N., Chen, J. Y., Zhou, M. J., Zhou, D. H., Chen, Z., Huang, Z. X., Xie, Y. X., Qiao, G. L., & Tu, X. H. (2024). WTAP‐induced N 6 ‐methyladenosine of PD‐L1 blocked T‐cell‐mediated antitumor activity under hypoxia in colorectal cancer. Cancer Science. https://doi.org/10.1111/cas.16136
Vancouver
Liu QZ, Zhang N, Chen JY, Zhou MJ, Zhou DH, Chen Z, et al. WTAP‐induced N 6 ‐methyladenosine of PD‐L1 blocked T‐cell‐mediated antitumor activity under hypoxia in colorectal cancer. Cancer Science. 2024. doi:10.1111/cas.16136
BibTeX
@article{Liu2024,
author = {Liu, Qi-Zhi and Zhang, Nan and Chen, Jun-Yi and Zhou, Min-Jun and Zhou, De-Hua and Chen, Zhuo and Huang, Zhen-Xing and Xie, Yu-Xiang and Qiao, Guang-Lei and Tu, Xiao-Huang},
title = {WTAP‐induced N 6 ‐methyladenosine of PD‐L1 blocked T‐cell‐mediated antitumor activity under hypoxia in colorectal cancer},
journal = {Cancer Science},
year = {2024},
doi = {10.1111/cas.16136}
}
EUVIMED